• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by The Oncology Institute Inc.

    8/20/24 8:20:55 AM ET
    $TOI
    Medical/Nursing Services
    Health Care
    Get the next $TOI alert in real time by email
    SC 13D/A 1 d864423dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)*

     

     

    The Oncology Institute, Inc.

    (Name of Issuer)

    Common Stock, par value of $0.0001 per share

    (Title of Class of Securities)

    23343Q100

    (CUSIP Number)

    Christopher Kersey

    Manager

    2100 McKinney Ave, Suite 1760

    Dallas, Texas 75201

    Tel: (214) 420-3481

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    August 16, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box: ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on following pages)

     

     

     


    Common Stock CUSIP No. 23343Q100

     

     1   

     NAME OF REPORTING PERSON

     

     Havencrest Healthcare Partners, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO (see Item 3)

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, United States

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0 shares

        8  

     SHARED VOTING POWER (1)

     

     100,000 shares

        9  

     SOLE DISPOSITIVE POWER

     

     0 shares

       10  

     SHARED DISPOSITIVE POWER (1)

     

     100,000 shares

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON (1)

     

     100,000 shares

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) (2)

     

     0.13%

    14  

     TYPE OF REPORTING PERSON

     

     PN

     

    (1)

    Consists of 100,000 shares of Common Stock (as defined herein) for which TOI HC I, LLC is the record owner and excludes 3,325,177 Earnout Shares (as defined herein) that may be issued to TOI HC I, LLC pursuant to the Merger Agreement (as defined herein). Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P.

    (2)

    Based on 75,490,489 shares of Common Stock of the Issuer (as defined herein) outstanding as of August 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2024.

     

    2


    Common Stock CUSIP No. 23343Q100

     

     1   

     NAME OF REPORTING PERSON

     

     Havencrest Healthcare Partners GP, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO (see Item 3)

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, United States

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     152,626 shares

        8  

     SHARED VOTING POWER (1)

     

     100,000 shares

        9  

     SOLE DISPOSITIVE POWER

     

     152,626 shares

       10  

     SHARED DISPOSITIVE POWER (1)

     

     100,000 shares

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON (1)

     

     252,626 shares

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) (2)

     

     0.33%

    14  

     TYPE OF REPORTING PERSON

     

     OO (Limited Liability Company)

     

    (1)

    Consists of 100,000 shares of Common Stock for which TOI HC I, LLC is the record owner and excludes 3,325,177 Earnout Shares that may be issued to TOI HC I, LLC pursuant to the Merger Agreement. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P.

    (2)

    Based on 75,490,489 shares of Common Stock of the Issuer outstanding as of August 6, 2024.

     

    3


    Common Stock CUSIP No. 23343Q100

     

     1   

     NAME OF REPORTING PERSON

     

     TOI HC I, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO (see Item 3)

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, United States

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0 shares

        8  

     SHARED VOTING POWER (1)

     

     100,000 shares

        9  

     SOLE DISPOSITIVE POWER

     

     0 shares

       10  

     SHARED DISPOSITIVE POWER (1)

     

     100,000 shares

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON (1)

     

     100,000 shares

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) (2)

     

     0.13%

    14  

     TYPE OF REPORTING PERSON

     

     OO (Limited Liability Company)

     

    (1)

    TOI HC I, LLC is the record owner of the shares and this amount excludes 3,325,177 Earnout Shares that may be issued to TOI HC I, LLC pursuant to the Merger Agreement.

    (2)

    Based on 75,490,489 shares of Common Stock of the Issuer outstanding as of August 6, 2024.

     

     

    4


    Explanatory Note

    The following constitutes Amendment No. 5 (“Amendment No. 5”) to the Schedule 13D filed by the undersigned with the Securities and Exchange Commission (the “SEC”) on November 22, 2021 (the “Original Schedule 13D”). This Amendment No. 5 amends the Original Schedule 13D as specifically set forth herein.

    Item 5. Interest in Securities of the Issuer.

    Paragraphs (a) and (c) of Item 5 are hereby amended and restated as follows:

    (a) Based on the 75,490,48973 shares of the Issuer’s Common Stock outstanding as of August 6, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024, the shares of Common Stock held by the Reporting Persons constitute 0.33% of the outstanding shares of Common Stock of the Issuer.

    Each Reporting Person disclaims beneficial ownership of the reported Common Stock except to the extent of such Reporting Person’s pecuniary interest therein, and this statement shall not be deemed an admission that such Reporting Person is the beneficial owner of the reported Common Stock for the purposes of Section 13(d) of the Act or any other purpose.

    The shares of the Issuer’s Common Stock reported in this Item 5 do not include the Earnout Shares described in Item 3 above.

    (c) The information contained in Item 4 is incorporated by reference herein. Except as set forth below or as disclosed herein, none of the Reporting Persons, or to the Reporting Persons’ knowledge, the persons set forth on Schedule I of this Amendment No. 5 has effected transactions in the Common Stock in the past 60 days.

    On August 16, 2024, TOI HC I, LLC distributed an aggregate of 8,701,823 shares of the Issuer’s Common Stock in a pro-rata in-kind distribution to its members in accordance with the governing documents of TOI HC I, LLC (the “TOI HC 1 Distribution”).

    Also on August 16, 2024, following the TOI HC 1 Distribution, Havencrest Healthcare Partners, L.P. made a further pro-rata in-kind distribution of the 7,631,418 shares it received in the TOI HC 1 Distribution to its limited partners in accordance with the governing documents of Havencrest Healthcare Partners, L.P.

     

    5


    SCHEDULE I

    Havencrest Healthcare Partners, L.P.

    The business and operations of Havencrest Healthcare Partners, L.P. are managed by its general partner, Havencrest Healthcare Partners GP, LLC, as set forth below.

    Havencrest Healthcare Partners GP, LLC

    The name, function, citizenship, and present principal occupation or employment for the officers of Havencrest Healthcare Partners GP, LLC are set forth below. Unless otherwise indicated below, the business address of each officer listed below is 2100 McKinney Avenue, Suite 1760, Dallas, TX 75201.

     

    Name

      

    Position with Reporting
    Person

      

    Principal Occupation/Business

      

    Citizenship

       No. Shares
    Held
     

    Christopher W. Kersey

       Manager and President    Founding Managing Partner of Havencrest Capital Management    United States      0  

    Randy Chappel

       Manager    Managing Director, Hersh Family Investments    United States      0  

    Tom White

       Manager    Vice President and Controller of BEPCO, L.P.    United States      0  

    Matthew Shofner

       Vice President, Secretary and Treasurer    Partner of Havencrest Capital Management    United States      0  

    TOI HC I, LLC

    The name, function, citizenship, and present principal occupation or employment for the managers of TOI HC I, LLC are set forth below. Unless otherwise indicated below, (i) each occupation set forth opposite the individual’s name refers to employment with Havencrest Healthcare Partners, L.P. and (ii) the business address of each manager listed below is 2100 McKinney Avenue, Suite 1760, Dallas, TX 75201.

     

    Name

      

    Position with Reporting
    Person

      

    Principal Occupation/Business

      

    Citizenship

       No. Shares
    Held
     

    Christopher W. Kersey

       Manager    Founding Managing Partner of Havencrest Capital Management    United States      0  

    Matthew Shofner

       Manager    Partner of Havencrest Capital Management    United States      0  

    Matthew Cline

       Manager    Vice President of Havencrest Capital Management    United States      0  

     

    6


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    August 20, 2024     HAVENCREST HEALTHCARE PARTNERS, L.P.
        By:   Havencrest Healthcare Partners GP, LLC, its general partner
        By:  

    /s/ Matthew Shofner

        Name:   Matthew Shofner
        Title:   Vice President, Treasurer and Secretary
        HAVENCREST HEALTHCARE PARTNERS, GP, LLC
        By:  

    /s/ Matthew Shofner

        Name:   Matthew Shofner
        Title:   Vice President, Treasurer and Secretary
        TOI HC I, LLC
        By:  

    /s/ Matthew Shofner

        Name:   Matthew Shofner
        Title:   Manager

     

    7

    Get the next $TOI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TOI

    DatePrice TargetRatingAnalyst
    2/26/2024$2.50Buy
    Jefferies
    9/14/2022$7.00Buy
    Guggenheim
    8/15/2022$10.00Buy
    Jefferies
    More analyst ratings

    $TOI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • The Oncology Institute to Present at Upcoming ASCO Annual Meeting on High-Value Cancer Care Model Outcomes Showing Cost Savings and Lower Hospitalization Rates

      CERRITOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI)("TOI"), one of the largest value-based oncology groups in the United States, announced today that it has been selected to present an abstract at the upcoming ASCO Annual Meeting further validating cost savings and reduced hospitalizations associated with its unique High-Value Cancer Care (HVCC) model*. The study shares new data supporting prior publications which demonstrate superior outcomes for acute-care patients when enrolled in the TOI HVCC model. "Without compromising on the clinical outcomes for our oncology patients, TOI has again demonstrated the ability to drive down both Emergency Depar

      5/8/25 8:00:10 AM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • The Oncology Institute Announces First Quarter 2025 Earnings Release Date and Conference Call

      CERRITOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2025 financial results after the market close on Wednesday, May 14, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and t

      4/23/25 8:00:46 AM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • The Oncology Institute of Hope and Innovation Expands Research Partnership with Helios Clinical Across Markets, Enhancing Access to Cutting-Edge Cancer Trials

      CERRITOS, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), a pioneer in value-based community oncology care, is proud to announce an enterprise-wide expansion of its strategic partnership with Helios Clinical Research, a nationally recognized research site network. This initiative builds upon a successful collaboration in Florida and reflects TOI's ongoing commitment to integrating clinical research into community oncology settings. "Expanding our research collaboration with Helios Clinical is a natural next step," said Daniel Virnich, MD, CEO at TOI. "They've proven to be a highly capable partner, helping us streamline study a

      4/22/25 4:05:39 PM ET
      $TOI
      Medical/Nursing Services
      Health Care

    $TOI
    SEC Filings

    See more
    • SEC Form S-3 filed by The Oncology Institute Inc.

      S-3 - Oncology Institute, Inc. (0001799191) (Filer)

      5/9/25 2:57:15 PM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • The Oncology Institute Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Oncology Institute, Inc. (0001799191) (Filer)

      5/8/25 4:55:27 PM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • The Oncology Institute Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Oncology Institute, Inc. (0001799191) (Filer)

      5/7/25 4:30:27 PM ET
      $TOI
      Medical/Nursing Services
      Health Care

    $TOI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies resumed coverage on The Oncology Institute with a new price target

      Jefferies resumed coverage of The Oncology Institute with a rating of Buy and set a new price target of $2.50

      2/26/24 8:25:21 AM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • Guggenheim initiated coverage on The Oncology Institute with a new price target

      Guggenheim initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $7.00

      9/14/22 9:25:17 AM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • Jefferies initiated coverage on The Oncology Institute with a new price target

      Jefferies initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $10.00

      8/15/22 9:26:19 AM ET
      $TOI
      Medical/Nursing Services
      Health Care

    $TOI
    Leadership Updates

    Live Leadership Updates

    See more
    • Jordan McInerney Appointed as Chief Development Officer of The Oncology Institute

      CERRITOS, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. and its affiliates (NASDAQ:TOI) is pleased to announce the appointment of Jordan McInerney as the new Chief Development Officer (CDO), effective April 1, 2024. In this role, Mr. McInerney will spearhead growth initiatives for The Oncology Institute across diverse markets, including cultivating new partnerships with payors, driving M&A processes for acquisition targets, and establishing MSO platforms to deliver value-based oncology care nationwide. Bringing over 15 years of healthcare leadership, McInerney most recently served as the Chief Operations Officer of HOPCo Network Solutions, a subsidiary of Hea

      4/8/24 8:00:00 AM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • The Oncology Institute Names Jeremy Castle as Chief Operations Officer

      CERRITOS, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) has announced the appointment of Jeremy Castle, MBA, as Chief Operations Officer, effective September 5, 2023. In this role, Mr. Castle leads enterprise field and central operations, pharmacy, real estate, and practice integration, playing a key role in driving TOI's success as a public company. Mr. Castle joins TOI with over 15 years of oncology industry experience, and has a track record of driving growth and profitability for multi-state physician groups. He has had other senior leadership positions, including Mr. Castle having previously served as the Chief Operating Officer for United Urolog

      10/11/23 4:05:00 PM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • The Oncology Institute Announces Leadership Transition

      CERRITOS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today announced that, by mutual agreement with the Board of Directors, Brad Hively will step down as Chief Executive Officer effective June 30, 2023. Dr. Daniel Virnich, the current President of TOI, will become CEO. Mr. Hively will transition to the role of Vice Chairman of the Board of Directors. Dr. Daniel Virnich has been with The Oncology Institute since 2020, initially as Chief Operating Officer before being promoted to President. He joined TOI from DaVita where he was most recently Pres

      6/12/23 6:00:00 AM ET
      $TOI
      Medical/Nursing Services
      Health Care

    $TOI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Hively Brad bought $47,168 worth of shares (45,280 units at $1.04), increasing direct ownership by 7% to 712,033 units (SEC Form 4)

      4/A - Oncology Institute, Inc. (0001799191) (Issuer)

      4/28/25 7:20:14 PM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • Chief Medical Officer Podnos Yale was granted 157,088 shares, increasing direct ownership by 199% to 236,137 units (SEC Form 4)

      4 - Oncology Institute, Inc. (0001799191) (Issuer)

      4/2/25 6:13:01 PM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • Chief Financial Officer Carter Robert Ross was granted 197,368 shares, increasing direct ownership by 501% to 236,775 units (SEC Form 4)

      4 - Oncology Institute, Inc. (0001799191) (Issuer)

      4/2/25 5:22:47 PM ET
      $TOI
      Medical/Nursing Services
      Health Care

    $TOI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by The Oncology Institute Inc.

      SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

      8/20/24 8:20:55 AM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13D/A filed by The Oncology Institute Inc. (Amendment)

      SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

      1/2/24 5:06:50 PM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G/A filed by The Oncology Institute Inc. (Amendment)

      SC 13G/A - Oncology Institute, Inc. (0001799191) (Subject)

      7/10/23 10:20:11 AM ET
      $TOI
      Medical/Nursing Services
      Health Care

    $TOI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Hively Brad bought $47,168 worth of shares (45,280 units at $1.04), increasing direct ownership by 7% to 712,033 units (SEC Form 4)

      4/A - Oncology Institute, Inc. (0001799191) (Issuer)

      4/28/25 7:20:14 PM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • Chief Executive Officer Virnich Daniel bought $23,584 worth of shares (22,640 units at $1.04), increasing direct ownership by 3% to 724,363 units (SEC Form 4)

      4 - Oncology Institute, Inc. (0001799191) (Issuer)

      3/28/25 5:50:27 PM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • Chief Medical Officer Podnos Yale bought $9,434 worth of shares (9,056 units at $1.04), increasing direct ownership by 13% to 79,049 units (SEC Form 4)

      4 - Oncology Institute, Inc. (0001799191) (Issuer)

      3/28/25 5:48:39 PM ET
      $TOI
      Medical/Nursing Services
      Health Care

    $TOI
    Financials

    Live finance-specific insights

    See more
    • The Oncology Institute Announces First Quarter 2025 Earnings Release Date and Conference Call

      CERRITOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2025 financial results after the market close on Wednesday, May 14, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and t

      4/23/25 8:00:46 AM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • The Oncology Institute Reports Fourth Quarter and Full Year 2024 Financial Results and Guidance for 2025

      CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2024. Recent Operational Highlights Cash flow from operations in Q4 2024 was approximately $4.2 million, due to disciplined working capital management that saw improvements across receivables, inventory, and payables.Selling, general, and administrative expenses decreased 12% in Q4 2024 as compared to the prior year period, as a result of our ongoing efforts to streamline operations, improve efficiency, and o

      3/24/25 6:01:10 AM ET
      $TOI
      Medical/Nursing Services
      Health Care
    • The Oncology Institute Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Conference Call

      CERRITOS, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its fourth quarter and full year 2024 financial results after the market close on Tuesday, March 25, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the

      3/4/25 8:00:30 AM ET
      $TOI
      Medical/Nursing Services
      Health Care